Evidence map›Paper›PMID 27329735›Full record

ArticleEuropean journal of human genetics : EJHG2016

When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.

B Meiser, V F Quinn, M Gleeson, J Kirk, K M Tucker, B Rahman, C Saunders, K J Watts, M Peate, E Geelhoed and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

B MeiserPrince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
V F QuinnPrince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
M GleesonHunter Family Cancer Service, Waratah, NSW, Australia.
J KirkFamilial Cancer Service, Westmead Hospital, Westmead, NSW, Australia.
K M TuckerHereditary Cancer Clinic, Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia.
B RahmanPrince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
C SaundersSchool of Surgery, University of Western Australia, Crawley, WA, Australia.
K J WattsPrince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
M PeatePrince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
E GeelhoedSchool of Population Health, University of Western Australia, Crawley, WA, Australia.
K Barlow-StewartSydney Medical School-Northern, University of Sydney, Sydney, NSW, Australia.
M FieldRoyal North Shore Hospital, St Leonards, NSW, Australia.
M HarrisMonash Health, Melbourne, VIC, Australia.
Y C AntillFamilial Cancer Centre, Cabrini Health, Melbourne, VIC, Australia.
G MitchellFamilial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
UNSW Sydney · AUPeter MacCallum Cancer Centre · AURoyal Women's Hospital · AUThe University of Sydney · AUThe University of Western Australia · AUWestmead Hospital · AUCabrini Hospital · AURoyal North Shore Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selection of women for treatment-focused genetic testing (TFGT) following a new diagnosis of breast cancer is changing. Increasingly a patient's age and tumour characteristics rather than only their family history are driving access to TFGT, but little is known about the impact of receiving carrier-positive results in individuals with no family history of cancer. This study assesses the role of knowledge of a family history of cancer on psychosocial adjustment to TFGT in both women with and without mutation carrier-positive results. In-depth semistructured interviews were conducted with 20 women who had undergone TFGT, and who had been purposively sampled to represent women both family history and carrier status, and subjected to a rigorous qualitative analysis. It was found that mutation carriers without a family history reported difficulties in making surgical decisions quickly, while in carriers with a family history, a decision regarding surgery, electing for bilateral mastectomy (BM), had often already been made before receipt of their result. Long-term adjustment to a mutation-positive result was hindered by a sense of isolation not only by those without a family history but also those with a family history who lacked an affected relative with whom they could identify. Women with a family history who had no mutation identified and who had not elected BM reported a lack of closure following TFGT. These findings indicate support deficits hindering adjustment to positive TFGT results for women with and without a family history, particularly in regard to immediate decision-making about risk-reducing surgery.

Indexed as

Genetic TestingMutationTruth DisclosureAdultBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsFemaleHealth Knowledge, Attitudes, PracticeHeterozygoteHumansMiddle AgedSurveys and QuestionnairesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID27329735
PMCPMC5110066
OpenAlexW2471652627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.